International Journal of Cardiovascular Imaging

One of the best lectures I have ever attended! Only Elazar Edelman can mix together endothelium, quantum physics, history, philosophy, determinism vs heuristics, through the lens of modernism Love the reenactment of the famous image of Laennec auscultation! (2nd photo) @DLBHATTMD

Deep dive into late breaking clinical trials presented at #ACC2025 happening now! S100 Packed room. Great discussants. Join us! 👉🏽WARRIOR 👉🏽SOUL 👉🏽STRIDE 👉🏽lorundrostat (Aldo synthase inhibitor)

Another summit (see what I did here?) in the HFpEF revolution! The dual GLP1/GIP mimetic tirzepatide improves outcomes in HFpEF with obesity! SUMMIT trial showed 38% ⬇️ in HF outcomes (=time-to-first HFH, oral diuretic intensification and CV death)!! investor.lilly.com/news-releases/…

So thrilled to have the extraordinary and amazingly talented clinician @JeffTeuteberg as our Visiting Professorship at @MountSinaiHeart Leading the change for biomarkers to replace cardiac biopsy in cardiac transplant surveillance @DLBHATTMD @dranulala @spinneymd @DonnaMancini11

What a tour de force by the amazing @PamTaubMD as Visiting Professor at @MountSinaiHear! She masterfully took us through her journey from cardiometabolism to time-restricted eating to POTS to Long Covid, all with impeccable scientific accumen and humility! @DLBHATTMD

Very proud to be invited to lecture at #AHA2023 about dual SGLT1/2 inhibition as a novel strategy for HFpEF! Saturday 11/11 at 3.15-4.30pm to learn HFpEF therapies from amazing experts @mvaduganathan @andrewjsauer @FudimMarat @HFpEF @KMAlexanderMD @JenHoCardiology @RBPatelMD

Wow! An SGLT2i is sold at $47.85!!!! (shipping included) 🥳🍾🎉🤑💸 That is 8% of the going price of empagliflozin or dapagliflozin!! Caveat: Only indication in T2DM (not HF or CKD) fiercepharma.com/pharma/theraco… @ChristosArgyrop @JonathanDavisHF @AndrewJSauer @hvanspall @dranulala

I have learnt so many concepts about RV evaluation from thr master himself, the one and only @RyanTedfordMD, in the Grand Rounds at #McMaster organized by @hvanspall Importance of RV/PA coupling over contractility, of exercise/pharmacological reserve over at-rest evaluation,…

Should we consider increased ketone body levels as one of the mechanisms of action involved in the cardiorenal benefit of SGLT2i? Our recent article supports this concept! @santosgallegoMD @RequenaIbanez @dlbhattmd @IcahnMountSinai @SinaiCards ahajournals.org/doi/abs/10.116…

Everything you wanted to know about the CLEAR-Outcomes trial, but were afraid to ask. Read my view on the latest @secardiologia blog entry LDL, the lower the better, the earlier the better! secardiologia.es/blog/14179-que… @lipidmir @ResiSec #cardioed #meded @Capijorge1

"EMPULSE: en insuficiencia cardiaca aguda, empagliflozina causa mejoría de la congestión temprana, efectiva y sostenida en el tiempo, que se asocia con beneficio clínico a largo plazo", señala @santosgallegoMD. #BlogSEC @jovenesSEC ow.ly/yP4j50MV3xk

With every passing day I learn that @SantosGallegoMD is an expert on another topic (SGLT2i, Spanish wine, opera, Futbol, tapas, bourbon…the list is endless). @rachkataria and @JonathanDavisHF decided that he is the most interesting man in the world. (#AHA22 edition)